Biogen expects to incur approximately $2 million in pre-tax acquired in-process research and development, upfront, and milestone expenses for the third quarter of 2025. This charge is anticipated to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.01 for the period. This disclosure provides investors with a preliminary estimate of how R&D-related collaboration and licensing costs will impact the company's upcoming quarterly earnings.
